These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 22511699)

  • 21. Morphine and hydromorphone for postoperative analgesia: focus on safety.
    Golembiewski JA
    J Perianesth Nurs; 2003 Apr; 18(2):120-2. PubMed ID: 12710006
    [No Abstract]   [Full Text] [Related]  

  • 22. The side effects of morphine and hydromorphone patient-controlled analgesia.
    Hong D; Flood P; Diaz G
    Anesth Analg; 2008 Oct; 107(4):1384-9. PubMed ID: 18806056
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Excretion profile of hydrocodone, hydromorphone and norhydrocodone in urine following single dose administration of hydrocodone to healthy volunteers.
    Valtier S; Bebarta VS
    J Anal Toxicol; 2012 Sep; 36(7):507-14. PubMed ID: 22782534
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and efficacy of hydromorphone as an analgesic alternative to morphine in acute pain: a randomized clinical trial.
    Chang AK; Bijur PE; Meyer RH; Kenny MK; Solorzano C; Gallagher EJ
    Ann Emerg Med; 2006 Aug; 48(2):164-72. PubMed ID: 16857467
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Evidence that morphine is metabolized to hydromorphone but not to oxymorphone.
    Cone EJ; Caplan YH; Moser F; Robert T; Black D
    J Anal Toxicol; 2008 May; 32(4):319-23. PubMed ID: 18430301
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Neuroexcitatory effects of morphine and hydromorphone: evidence implicating the 3-glucuronide metabolites.
    Smith MT
    Clin Exp Pharmacol Physiol; 2000 Jul; 27(7):524-8. PubMed ID: 10874511
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics and physiological effects of intravenous hydromorphone in conscious dogs.
    Guedes AG; Papich MG; Rude EP; Rider MA
    J Vet Pharmacol Ther; 2008 Aug; 31(4):334-43. PubMed ID: 18638294
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of OROS hydromorphone in the management of cancer pain.
    Gardner-Nix J; Mercadante S
    Pain Pract; 2010; 10(1):72-7. PubMed ID: 19863749
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Patient selection and outcomes using a low-dose intrathecal opioid trialing method for chronic nonmalignant pain.
    Grider JS; Harned ME; Etscheidt MA
    Pain Physician; 2011; 14(4):343-51. PubMed ID: 21785477
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Disposition of morphine in the rat isolated perfused kidney: concentration ranging studies.
    Shanahan KM; Evans AM; Nation RL
    J Pharmacol Exp Ther; 1997 Sep; 282(3):1518-25. PubMed ID: 9316867
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of plasma histamine levels after intravenous administration of hydromorphone and morphine in dogs.
    Guedes AG; Papich MG; Rude EP; Rider MA
    J Vet Pharmacol Ther; 2007 Dec; 30(6):516-22. PubMed ID: 17991219
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multicenter, open-label, prospective evaluation of the conversion from previous opioid analgesics to extended-release hydromorphone hydrochloride administered every 24 hours to patients with persistent moderate to severe pain.
    Weinstein SM; Shi M; Buckley BJ; Kwarcinski MA
    Clin Ther; 2006 Jan; 28(1):86-98. PubMed ID: 16490582
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical analgesic equivalence for morphine and hydromorphone with prolonged PCA.
    Dunbar PJ; Chapman CR; Buckley FP; Gavrin JR
    Pain; 1996 Dec; 68(2-3):265-70. PubMed ID: 9121813
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Trend in opioids use for chronic pain treatment at Clalit Health Services (2000-2004)].
    Freud T; Brill S; Sherf M; Singer Y; Vardy D; Shvartzman P
    Harefuah; 2007 Dec; 146(12):928-31, 999. PubMed ID: 18254442
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adverse effects in hospice patients with chronic kidney disease receiving hydromorphone.
    Paramanandam G; Prommer E; Schwenke DC
    J Palliat Med; 2011 Sep; 14(9):1029-33. PubMed ID: 21823925
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of hydromorphone (Dilaudid) and morphine for patients with hepatic and renal impairment.
    Razaq M; Balicas M; Mankan N
    Am J Ther; 2007; 14(4):414-6. PubMed ID: 17667220
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparing the efficacy and safety of continuous epidural analgesia in abdominal and urological surgery between two opioids with different kinetic properties: morphine and sufentanyl.
    Delvecchio L; Bettinelli S; Klersy C; Allegri M; Cavalloro F; Braschi A
    Minerva Anestesiol; 2008 Mar; 74(3):69-76. PubMed ID: 18288069
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Choosing the unit of measurement counts: the use of oral morphine equivalents in studies of opioid consumption is a useful addition to defined daily doses.
    Svendsen K; Borchgrevink P; Fredheim O; Hamunen K; Mellbye A; Dale O
    Palliat Med; 2011 Oct; 25(7):725-32. PubMed ID: 21378066
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The intravenous to oral relative milligram potency ratio of morphine during chronic dosing in cancer pain.
    Lasheen W; Walsh D; Mahmoud F; Sarhill N; Rivera N; Davis M; Lagman R; Legrand S
    Palliat Med; 2010 Jan; 24(1):9-16. PubMed ID: 19910396
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Morphine or hydromorphone: which should be preferred? A systematic review.
    Spénard S; Gélinas C; D Trottier E; Tremblay-Racine F; Kleiber N
    Arch Dis Child; 2021 Oct; 106(10):1002-1009. PubMed ID: 33461958
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.